Show simple item record

dc.contributor.authorWang, Shixia
dc.contributor.authorYates, Nicole L
dc.contributor.authorPollara, Justin
dc.contributor.authorVoronin, Yegor
dc.contributor.authorStanfield-Oakley, Sherry
dc.contributor.authorHan, Dong
dc.contributor.authorHu, Guangnan
dc.contributor.authorLi, Wei
dc.contributor.authorFerrari, Guido
dc.contributor.authorTomaras, Georgia D
dc.contributor.authorLu, Shan
dc.date.accessioned2023-07-19T19:29:51Z
dc.date.available2023-07-19T19:29:51Z
dc.date.issued2022-02-09
dc.identifier.citationWang S, Yates NL, Pollara J, Voronin Y, Stanfield-Oakley S, Han D, Hu G, Li W, Ferrari G, Tomaras GD, Lu S. Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. NPJ Vaccines. 2022 Feb 9;7(1):18. doi: 10.1038/s41541-022-00441-9. PMID: 35140230; PMCID: PMC8828892.en_US
dc.identifier.eissn2059-0105
dc.identifier.doi10.1038/s41541-022-00441-9en_US
dc.identifier.pmid35140230
dc.identifier.urihttp://hdl.handle.net/20.500.14038/52314
dc.description.abstractSince publishing our original reports on the safety and immunogenicity of a polyvalent DNA prime-protein boost HIV vaccine (PDPHV) which elicited high titer antibody responses with broad specificity, neutralizing activities to multiple HIV-1 subtypes, as well as poly-functional T cell responses, accumulated findings from other HIV vaccine studies indicated the important roles of Ig isotype distribution, Fc medicated functions and the persistence of memory immune responses which were not studied in previous PDPHV related reports. The current report provides further detailed characterization of these parameters in human volunteers receiving the PDPHV regimen. Antibody responses were assessed using IgG isotype and gp70-V1V2-binding ELISAs, peptide arrays, and antibody-dependent cellular cytotoxicity (ADCC) assays. B cell ELISPOT was used to detect gp120-specific memory B cells. Our results showed that the gp120-specific antibodies were primarily of the IgG1 isotype. HIV-1 envelope protein variable regions V1 and V2 were actively targeted by the antibodies as determined by specific binding to both peptide and V1V2-carrying scaffolds. The antibodies showed potent and broad ADCC responses. Finally, the B cell ELISPOT analysis demonstrated persistence of gp120-specific memory B cells for at least 6 months after the last dose. These data indicate that broadly reactive binding Abs and ADCC responses as well as durable gp120-specific memory B cells were elicited by the polyvalent heterologous prime-boost vaccination regimens and showed great promise as a candidate HIV vaccine.en_US
dc.language.isoenen_US
dc.relation.ispartofNPJ Vaccinesen_US
dc.relation.urlhttps://doi.org/10.1038/s41541-022-00441-9en_US
dc.rightsOpen Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. © The Author(s) 2022en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPublic healthen_US
dc.subjectVaccinesen_US
dc.titleBroadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHVen_US
dc.typeJournal Articleen_US
dc.source.journaltitleNPJ vaccines
dc.source.volume7
dc.source.issue1
dc.source.beginpage18
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland
dc.identifier.journalNPJ vaccines
refterms.dateFOA2023-07-19T19:29:52Z
dc.contributor.departmentMedicineen_US


Files in this item

Thumbnail
Name:
s41541-022-00441-9.pdf
Size:
994.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Open Access: This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2022
Except where otherwise noted, this item's license is described as Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. © The Author(s) 2022